Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis

Neuro-Oncology

Volumn 17, Issue 4, 2015, Pages 545-554

  Bai, Ren Yuan ^a   Staedtke, Verena ^a   Rudin, Charles M ^b   Bunz, Fred ^a   Riggins, Gregory J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; Mebendazole; Medulloblastoma; VEGF; VEGFR2

Indexed keywords

ADENOSINE TRIPHOSPHATE; MEBENDAZOLE; PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 KINASE; VASCULOTROPIN RECEPTOR 2; VISMODEGIB; ANTINEOPLASTIC AGENT;

ALLOGRAFT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO STUDY; LENTIVIRINAE; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MOUSE; MUTANT; NONHUMAN; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; CEREBELLAR NEOPLASMS; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; FEMALE; HUMANS; MEBENDAZOLE; MEDULLOBLASTOMA; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84933509205     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou234     Document Type: Article

References (37)

1. Klesse LJ, Bowers DC. Childhood medulloblastoma: current status of biology and treatment. CNS Drugs. 2010;24(4):285-301.
2. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12(12):818-834.
3. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465-472.
4. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173-1178.
5. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326(5952):572-574.
6. Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med. 2011;17(6):301-312.
7. Bai RY, Staedtke V, Aprhys CM, et al. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011;13(9):974-982.
8. Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov. 2009;8(11):892-909.
9. Doudican NA, Byron SA, Pollock PM, et al. XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs. 2013;24(2):181-188.
10. Doudican N, Rodriguez A, Osman I, et al. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res. 2008;6(8):1308-1315.
11. Dakshanamurthy S, Issa NT, Assefnia S, et al. Predicting new indications for approved drugs using a proteochemometric method. J Med Chem. 2012;55(15):6832-6848.
12. Keles GE, Berger MS, Srinivasan J, et al. Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol Res. 1995;7(10-11):493-503.
13. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2012;23(1):23-34.
14. Munst GJ, Karlaganis G, Bircher J. Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results. Eur J Clin Pharmacol. 1980;17(5):375-378.
15. Bai RY, Koester C, Ouyang T, et al. SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling. Nat Cell Biol. 2002;4(3):181-190.
16. Bai RY, Staedtke V, Lidov HG, et al. OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res. 2012;72(22):5988-6001.
17. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995;36(2):169-180.
18. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871-882.
19. Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-Adependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. Embo J. 2001;20(11):2768-2778.
20. Holmqvist K, Cross MJ, Rolny C, et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004;279(21):22267-22275.
21. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1 (+/2) p53 (2/2) mice. Cancer Cell. 2004;6(3):229-240.
22. Northcott PA, Korshunov A, Pfister SM, et al. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol. 2012;8(6):340-351.
23. Adamson DC, Shi Q, Wortham M, et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res. 2010;70(1):181-191.
24. Bai R, Siu IM, Tyler BM, et al. Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Neuro Oncol. 2010;12(7):655-663.
25. Cheng SY, Nagane M, Huang HS, et al. Intracerebral tumorassociated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A. 1997;94(22):12081-12087.
26. Jung S, Moon KS, Jung TY, et al. Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage. J Neurooncol. 2006;76(3):257-263.
27. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010;10(7):505-514.
28. Jin Kim Y, Hyun Kim C, Hwan Cheong J, et al. Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas. Tumori. 2011;97(5):639-646.
29. Baluk P, McDonald DM. Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Ann N Y Acad Sci. 2008;1131:1-12.
30. Nygren P, Fryknas M, Agerup B, et al. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J Cancer Res Clin Oncol. 2013;139(12):2133-2140.
31. Kohler P. The biochemical basis of anthelmintic action and resistance. Int J Parasitol. 2001;31(4):336-345.
32. Argraves WS, Larue AC, Fleming PA, et al. VEGF signaling is required for the assembly but not the maintenance of embryonic blood vessels. Dev Dyn. 2002;225(3):298-304.
33. Lijnen HR, Scroyen I. Effect of vascular endothelial growth factor receptor 2 antagonism on adiposity in obese mice. J Mol Endocrinol. 2013;50(3):319-324.
34. von Baumgarten L, Brucker D, Tirniceru A, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res. 2011;17(19):6192-6205.
35. Narita Y. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Jpn J Clin Oncol. 2013;43(6):587-595.
36. Piha-Paul SA, Shin SJ, Vats T, et al. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res. 2014;34(4):1939-1945.
37. Sasaki J, Ramesh R, Chada S, et al. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002;1(13):1201-1209.